When does the fingolimod (Gilenya) patent expire?
Patent expiry depends on the specific country and the exact patent being considered, because drug intellectual property is typically split across multiple patents (for example, compound, formulation, and use patents) with different lifespans and legal events. Based on the information provided here, I can’t determine an exact global expiry date for fingolimod’s patents.
Why the expiry date can differ by country
Even for the same medicine (fingolimod), patent protection and related exclusivity can vary because:
- Different jurisdictions have different patent term calculations and “evergreening” filings.
- Some countries grant additional market exclusivities tied to regulatory approval rather than standard patent term.
- Patent terms can be extended or shortened due to prosecution history and legal rulings (and some patents may be invalidated or narrowed).
What people usually mean by “patent expiry” for fingolimod
Patients and competitors often use “patent expiry” to refer to one of several events:
- The end of the last relevant patent that blocks generic entry.
- The end of data exclusivity or market exclusivity (where it applies).
- The end of pediatric or other extensions (where granted).
Because fingolimod is approved and marketed in multiple countries under multiple regulatory regimes, the relevant date can be different depending on which legal barrier a generic company is trying to overcome.
What happens after patent expiry (generic/biosimilar timing)
After the relevant exclusivity/patent barriers end, manufacturers may be able to file and/or launch lower-cost versions, but timing can still be affected by:
- Whether patents are still active in that jurisdiction.
- Ongoing patent litigation.
- Regulatory requirements for generic approval and labeling.
Can fingolimod generics enter before the last patent expires?
Sometimes yes in part of the world if:
- The specific patents blocking generic approval have already expired or been found unenforceable/narrow.
- A manufacturer can launch for certain strengths/indications or via a pathway that is not blocked by the remaining patents.
But in many cases, companies still need clearance for the remaining “core” patents and any exclusivity protections in that country.
How to get the exact fingolimod expiry date you care about
If you tell me the country (for example, US, EU, UK, Canada, India) and whether you mean:
- the first generic launch,
- the last patent expiry, or
- data/market exclusivity expiry,
I can narrow the answer to the correct date or dates for that jurisdiction.
Sources
No sources were provided with the question, so I can’t cite any documents for fingolimod’s patent expiry date.